Overview
Tirzepatide is a 39-amino acid synthetic peptide designed as a single molecule that simultaneously activates both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). This dual mechanism — referred to as "twincretin" activity — differentiates tirzepatide from earlier GLP-1 mono-agonists and has been associated with more pronounced effects on body weight and glycemic parameters in clinical research programs. The peptide is acylated with a C20 fatty diacid moiety enabling albumin binding and achieving a half-life suitable for once-weekly dosing in clinical settings.
In Phase 3 clinical research, tirzepatide produced dose-dependent reductions in body weight and HbA1c that exceeded those observed with comparator GLP-1 receptor agonists. The relative contributions of GIP vs GLP-1 receptor engagement to these outcomes remains an active area of investigation, with particular interest in whether GIPR agonism augments, complements, or partially attenuates the gastrointestinal side effects associated with GLP-1R alone.
Mechanism of Research Interest
- GIP receptor agonism on β-cells amplifies glucose-dependent insulin secretion independently of GLP-1R
- GLP-1 receptor agonism provides glucose-lowering, gastric emptying delay, and central appetite reduction
- Combined GIPR/GLP-1R stimulation produces greater body weight reduction than GLP-1R alone in preclinical and clinical data
- GIPR agonism may reduce nausea limiting GLP-1R mono-agonist dose escalation
- Potential direct effects on adipocytes and CNS energy regulation via GIPR expression in these tissues
Specifications
| Full Name | Tirzepatide (LY3298176) |
| Receptor Targets | GIPR / GLP-1R (dual agonist) |
| Molecular Formula | C₂₂₅H₃₄₈N₄₈O₆₈ |
| MW | ~4,813.5 Da |
| CAS | 2023788-19-2 |
| Purity | ≥98% HPLC |
| Form | Lyophilized powder |
| Appearance | White to off-white powder |
| Storage Lyophilized | −20°C |
| Storage Reconstituted | 2–8°C, use within 4 weeks |
| Solubility | Sterile or bacteriostatic water |
Reconstitution
Reconstitution Protocol
Reconstitute with sterile or bacteriostatic water. Due to the C20 fatty acid modification, tirzepatide may require gentle agitation at room temperature before full dissolution. Add solvent slowly along the vial wall, gently swirl — do not vortex. Store reconstituted at 2–8°C, use within 4 weeks. Do not freeze reconstituted solution.
Quality & Purity
Every batch of Tirzepatide supplied by Trusty Peptide undergoes third-party HPLC testing to verify purity of ≥98%. A Certificate of Analysis (COA) is included with every order.
Research Use Only. Tirzepatide supplied by Trusty Peptide is intended strictly for laboratory and in vitro research purposes. It is not approved for human or veterinary use, and is not a medicine, drug, or nutritional supplement. By purchasing you confirm you are a qualified researcher using this compound for legitimate scientific research only.